We are live on ! Find out more
EPZM

Epizyme, Inc

Delisted

EPZM was delisted on the 11th of August, 2022.

99 hedge funds and large institutions have $485M invested in Epizyme, Inc in 2016 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 38 increasing their positions, 21 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

89% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 9

81% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 21

9% more funds holding

Funds holding: 9199 (+8)

13% less capital invested

Capital invested by funds: $556M → $485M (-$71M)

29% less funds holding in top 10

Funds holding in top 10: 75 (-2)

55% less call options, than puts

Call options by funds: $20K | Put options by funds: $44K

Holders
99
Holders Change
+8
Holders Change %
+8.79%
% of All Funds
2.64%
Holding in Top 10
5
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-28.57%
% of All Funds
0.13%
New
17
Increased
38
Reduced
21
Closed
9
Calls
$20K
Puts
$44K
Net Calls
-$24K
Net Calls Change
-$22K
Name Holding Trade Value Shares
Change
Change in
Stake
RhumbLine Advisers
51
RhumbLine Advisers
Massachusetts
$424K +$64K +5,740 +16%
AllianceBernstein
52
AllianceBernstein
Tennessee
$416K +$137K +12,300 +43%
Macquarie Group
53
Macquarie Group
Australia
$410K +$223K +20,000 +100%
Capital Fund Management (CFM)
54
Capital Fund Management (CFM)
France
$398K +$434K +38,900 New
Jacobs Levy Equity Management
55
Jacobs Levy Equity Management
New Jersey
$391K +$426K +38,200 New
New York State Common Retirement Fund
56
New York State Common Retirement Fund
New York
$387K +$36.8K +3,300 +10%
TI
57
Trexquant Investment
Connecticut
$387K +$421K +37,801 New
DekaBank Deutsche Girozentrale
58
DekaBank Deutsche Girozentrale
Germany
$346K +$95.9K +8,600 +35%
MLICM
59
Metropolitan Life Insurance Company (MetLife)
New York
$318K
Manulife (Manufacturers Life Insurance)
60
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$293K +$62.6K +5,618 +24%
WC
61
Woodstock Corp
Massachusetts
$282K +$307K +27,534 New
NFA
62
Nationwide Fund Advisors
Ohio
$268K
TAM
63
Tocqueville Asset Management
New York
$256K
AIG
64
American International Group
New York
$237K +$68.6K +6,155 +36%
VEA
65
Virtus ETF Advisers
New York
$223K +$59.7K +5,350 +33%
T. Rowe Price Associates
66
T. Rowe Price Associates
Maryland
$199K +$78.1K +7,000 +56%
BA
67
BlackRock Advisors
Delaware
$193K -$647 -58 -0.3%
ZIM
68
Zacks Investment Management
Illinois
$174K
Goldman Sachs
69
Goldman Sachs
New York
$165K +$9.71K +871 +6%
VOYA Investment Management
70
VOYA Investment Management
Georgia
$164K +$27.5K +2,464 +18%
JMPWA
71
JP Morgan Private Wealth Advisors
California
$162K
State Board of Administration of Florida Retirement System
72
State Board of Administration of Florida Retirement System
Florida
$157K +$23.4K +2,102 +16%
Renaissance Technologies
73
Renaissance Technologies
New York
$155K -$159K -14,300 -49%
SO
74
STRS Ohio
Ohio
$133K
Wells Fargo
75
Wells Fargo
California
$130K -$25.3K -2,270 -15%

EPZM Hedge Fund Activity: Q2 2016 in Review

99 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q2 2016, worth a combined $485M — down 13% from $556M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new EPZM positions and 9 closed out — a net gain of 8 holders — while 38 added to existing stakes and 21 trimmed.

The largest buyer was CQS Cayman, opening a new position worth an estimated $7.08M. The largest seller was EcoR1 Capital, cutting an estimated $9.41M.

  • 99 institutional investors held Epizyme, Inc (EPZM) as of Q2 2016, up from 91 in Q1 2016.
  • Funds reported $485M of Epizyme, Inc stock for Q2 2016, down 13% quarter-over-quarter.
  • 17 funds opened new Epizyme, Inc positions in Q2 2016 and 9 closed out, a net change of +8 holders.
  • The largest Epizyme, Inc buyer in Q2 2016 was CQS Cayman, an estimated $7.08M added.
  • The largest Epizyme, Inc seller in Q2 2016 was EcoR1 Capital, an estimated $9.41M sold.

Based on aggregated 13F filings for Q2 2016.